Germany-based clinical-stage biopharmaceutical company atai Life Sciences N.V. (ATAI) Tuesday announced positive results from its Phase 1 study of orally administered EMP-01, the R-enantiomer of MDMA or 3,4-methylenedioxy-methamphetamine.
In the pre-market session, shares are gaining more than 5%
The Phase 1, single-ascending dose, randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of EMP-01. Treatment-related adverse events were as expected.
The company said EMP-01 was well-tolerated, and treatment-related adverse events were all expected and generally dose-dependent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.